[ad_1]
Original title: Huizhi debuted at China International Import Expo and continued to deepen the Chinese market
At the third CIIE, Mylan andPfizerGlobal health formed by the Pultron mergerthe company—— 晖 致 (Viatris)companyBrandOfficially Revealed This is Huizhi in ChinamarketDebut.
“The CIIE is an important decision made by China to actively open its market to the world. It is a platform for global trade, providing new development opportunities for all walks of life, especially in the context of the current severe global pandemic. of COVID-19 “. The CIIE is still arriving on schedule, demonstrating the strong resilience and huge potential of the Chinese market. ” PfizerPultron Globalstrategy, Business development anddealAdvanced skillvice president, Huizhi’s futureBiggest chinaPresidentNi Xiangyang said, “China occupies a very important position in Huizhi’s development strategy. We must truly focus on the patient and draw on a wide range of treatment areas.”productAnd forward-thinking disease management concepts, and convey them to patients through strong business capabilities and advanced digital technology, so patients can easily enjoyqualityReliable, medicines and services protect people’s health at all stages of life and help a healthy China. “
The reporter learned that Huizhi is the world’s largest pharmaceutical company.PfizerA new multinational pharmaceutical company formed by the merger of the generic brand and mature pharmaceutical business unit Pultron and the larger generic pharmaceutical company Mylan.
Huizhi, soon to be established, will have a diversified product portfolio around the world, including approximately 1,400 compounds and biologics.
Currently in China, Huizhi has more than 20 world-renowned high-quality drugs, covering multiple treatment fields such as cardiovascular, mental health, urinary, pain, liver diseases and infections, orthopedics, rheumatism, and allergic reactions.
Among them, Lipitor and Luohuoxi, the iconic brand products in the cardio-cerebrovascular field from Puqiang, have been on the market in China for more than 20 years, benefiting tens of millions of patients; and men’s health.Star productsViagra has also been on the market for 20 years, bringing good news to many families.
Mylan’s unique products have a good reputation in the Chinese market, including Supifu, Ainida, Veguri, Lijialong, etc. In the field of liver diseases and infections, in addition to the products already on the market in China, Mylan has a broad product portfolio and a global product portfolio. Mylan is a world leader in the field of HIV treatment and has a variety of new AIDS drugs for sale or in development.
“Huizhi combines Pultron’s trusted iconic brand with Mylan’s broad and diversified portfolio of products, and is able to offer products in all major therapeutic areas.” Talking about Huizhi’s newly launched new drugs and future plans, Ni Xiangyang introduced In October this year, Viagra Coca-Cola Disintegrating Tablets imported from France were launched in China. The new dosage form is more comfortable to take, bringing good news to Chinese ED patients. In addition, in the field of rare diseases, Revanto was also approved this year. It is the first in China. Phosphodiesterase type 5 inhibitor approved for the treatment of pulmonary hypertension. “In the future, we will continue to deepen the Chinese market and provide more urgently needed drugs that are tailored to the needs of Chinese patients.”
The latest forecast from the Organization for Economic Cooperation and Development (OECD) shows that in the next 15 years, almost all OECD countries will spend on health care.IncreaseWill overcomeGDPIncrease. At the launch ceremony, Miao Tianxiang, Chairman and Chairman of Pfizer Power China and future Chairman of Huizhi Greater China, explained Huizhi’s core mission: “Rising healthcare spending, diversified and changing healthcare needs of people, making the current and future medical environment full of opportunities and challenges. Huizhi has 45,000 employees worldwide with extensive experience in science, production, quality, registration and medical affairs, serving patients in more than 165 countries and regions Service. We are committed to fulfilling our mission through ‘accessibility’, ‘leadership’ and ‘cooperation’, helping people around the world to live healthier lives at every stage of their lives. “
With rapid economic development, health and medical conditions are notableto get better, The average life expectancy of Chinese has increased from 35 years in 1949 to 77 years today China has entered an aging society and the degree is still deepening. Aging brings not only health problems, but also great challenges for economic development.
At this CIIE, the welfare of the people of Huizhi and ChinabackgroundIt will sign a cooperation agreement to support the national development of the “Guardian Online-Hypertension foundationInternet +Out-of-hospital management project “approved”The Internet+ “Innovative model helps patients form good blood pressure management habits, encourages medical staff to remotely monitor and guide patients outside the hospital, thereby increasing hypertension awareness and control rate .
In addition, during the CIIE, Huizhi will sign contracts and launch activities with partners for multiple projects, such as the China Pain Strategy Launch Event and the “Chronic Noncommunicable Diseases Medical Center” jointly established with the American College of Cardiology ( ACC). -Primary carejobsEducation Institute “, etc., look forward to working with partners to help China strengthen chronic disease management capabilities and improve grassrootsmedical serviceThe quality and availability of drugs.
(Article source:international financesNewspaper)
(Responsible editor: DF537)
I solemnly declare: The purpose of this information disclosed by Oriental Fortune.com is to spread more information and has nothing to do with this booth.
[ad_2]